17% ALK Mutation Detected in Lung Adenocarcinoma Genetic Testing, Should Targeted Therapy Continue After One Month of Crizotinib Use and NegativeALK?

Question

The genetic testing for lung adenocarcinoma shows a 17% ALK mutation. After one month of taking the targeted drug crizotinib, there has been no significant reduction in pleural effusion, and ALK has turned negative. Should the targeted therapy continue?

Answer

For patients with ALK-positive non-small cell lung cancer, targeted therapy is the preferred treatment. However, even if ALK turns negative, it may still be considered to continue using targeted drugs, depending on the patient’s specific condition and doctor’s advice.